1 Tube, 1 Week, Complete Results
DNA, RNA, Immunotherapy. Somatic and Hereditary. Blood and Tissue.
Your genes, right now.
Circulogene’s liquid biopsy process is based on the discovery that as tumors grow, they also die, releasing their DNA into the bloodstream. Circulogene’s liquid biopsy tumor DNA sequencing is the only test available that combines minimal volumes of blood and the most advanced next-generation sequencing (NGS) to monitor tumor-mutant DNA within well-characterized, well-documented, cancer-associated genes.
With just one tube of blood, Circulogene’s patented technology utilizes NGS to monitor known tumor mutations (approximately 3,000) in 50 established cancer-associated genes and further provides information on current FDA-approved treatment options.
Access
Minimal-volume input with maximal yield. One tube for all DNA/RNA/Immunotherapy means the access to patient’s blood is even less invasive.
Enrich
Patented enrichment technology locates and captures cell-free DNA, identifying and quantifying any tumor mutations for accurate reporting and monitoring.
Detect
Capable of testing 50 genes for approximately 3,000 possible mutations. Multimutation monitoring capabilities encompass a broad range of tumor profiles and allow for patient-centered precision medicine.
The Circulogene Advantage
Certificate of Compliance
Circulogene Theranostics
3125 Independence Drive, Suite 301
CLIA ID NUMBER: 01D2101075